Organon (OGN): Future Price to Earnings

Graphic logo of organon.com (OGN)

A stable roster of women's health experts ensures the resilience of Organon & Co. (OGN). The company's forward P/E ratio on the GURU.Markets terminal chart demonstrates a trend where the value of 3.80 represents the latest figure. Automated AI packaging lines support efficiency growth, while experienced management focuses on reducing debt load and optimizing business cash flows.

Projected Price to Earnings: organon.com (OGN) for 07/04/2022 - 11/12/2026

Organon Pharma (OGN) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Quotes Organon|OGN - Consensus Target
- stock exchange capitalization data:
Market Value Organon & Co|OGN - Total Enterprise Value
- balance sheet equity data:
Net Assets per Single Share Organon|OGN - Company Net Assets|Market Capitalization to Book Value Ratio organon.com|OGN - Company Assets
- debt level and financial liquidity data:
Debt to Equity Organon & Co.|OGN - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Organon & Co.|OGN - Company Cumulative Debt|Debt to Book Capitalization Ratio Organon & Co|OGN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Organon|Quick Ratio organon.com
- company profitability and valuation multiples indicators:
OGN - Net Profit|Expected Profit Organon & Co.|OGN - Price to Earnings Multiple|Future Price to Earnings Organon Corp|OGN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Organon & Co|OGN - Operating profit before amortization|Net earnings per share for the last 12 months Organon|OGN - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last 12 months organon.com|OGN - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Organon & Co.
Analysis of all company metrics:OGN Organon
Signature product of Organon & Co.

Forward P/E determines the stock value relative to expected net income, allowing investors to assess whether the current market price is fair. Analyzing the projected P/E valuation of Organon & Co. (OGN) reveals how ownership of unique patents in women's health and stable demand for contraceptives minimize the volatility of this ratio, confirming the fundamental resilience of the business.

Direct competitors

Projected Price to Earnings DARE (Daré Bioscience)|Projected Price to Earnings therapeuticsmd.com TXMD|Future Price to Earnings Palatin PTN